Overcoming multidrug resistance (MDR) in cancer in vitro and in vivo by a quinoline derivative
Multidrug resistance (MDR) mediated by the over expression of drug efflux protein P-
glycoprotein (P-gp) is one of the major impediments to successful treatment of cancer. P-gp …
glycoprotein (P-gp) is one of the major impediments to successful treatment of cancer. P-gp …
5-Oxohexahydroquinolines bearing 4-pyridyl methyl carboxylate as P-glycoprotein inhibitors and multidrug resistance reversal agents in cancer cells
S Ranjbar, FF Lashkarian, M Khoshneviszadeh… - Journal of Molecular …, 2023 - Elsevier
Multidrug resistance (MDR) limits the therapeutic effect of conventional chemotherapeutic
agents as well as novel targeted anticancer drugs. An important mechanism of MDR is the …
agents as well as novel targeted anticancer drugs. An important mechanism of MDR is the …
Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as P-glycoprotein-mediated multidrug resistance inhibitors
Y Gao, W Shi, J Cui, C Liu, X Bi, Z Li, W Huang… - Bioorganic & Medicinal …, 2018 - Elsevier
Multidrug resistance (MDR) is one of the main obstacles of clinical chemotherapy. A great
deal of research shows that the occurrence of drug resistance in various malignant tumors is …
deal of research shows that the occurrence of drug resistance in various malignant tumors is …
Novel 5-oxo-hexahydroquinoline derivatives: design, synthesis, in vitro P-glycoprotein-mediated multidrug resistance reversal profile and molecular dynamics …
Overexpression of the efflux pump P-glycoprotein (P-gp) is one of the important mechanisms
of multidrug resistance (MDR) in many tumor cells. In this study, 26 novel 5-oxo …
of multidrug resistance (MDR) in many tumor cells. In this study, 26 novel 5-oxo …
Tetrahydroquinolinone derivatives as potent P-glycoprotein inhibitors: design, synthesis, biological evaluation and molecular docking analysis
P-glycoprotein (P-gp) is a transmembrane efflux pump that has been associated with
ineffective cancer chemotherapy and multidrug resistance (MDR). Chemical inhibitors of P …
ineffective cancer chemotherapy and multidrug resistance (MDR). Chemical inhibitors of P …
Design, Synthesis, and Pharmacological Characterization of N-(4-(2 (6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)yl)ethyl)phenyl)quinazolin-4-amine Derivatives …
Q Qiu, B Liu, J Cui, Z Li, X Deng, H Qiang… - Journal of Medicinal …, 2017 - ACS Publications
P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is a principal obstacle for
successful cancer chemotherapy. A novel P-gp inhibitor with a quinazoline scaffold, 12k …
successful cancer chemotherapy. A novel P-gp inhibitor with a quinazoline scaffold, 12k …
Overcoming multidrug resistance in human lung cancer with novel benzo [a] quinolizin-4-ones
Y Kanintronkul, R Worayuthakarn, N Thasana… - Anticancer …, 2011 - ar.iiarjournals.org
Aim: To investigate the ability of synthetic benzo [a] quinolizin-4-one derivatives to reverse
multidrug resistance (MDR) in lung cancer cells. Materials and Methods: A cell line with …
multidrug resistance (MDR) in lung cancer cells. Materials and Methods: A cell line with …
Design, synthesis and biological evaluation of novel phenylfuran-bisamide derivatives as P-glycoprotein inhibitors against multidrug resistance in MCF-7/ADR cell
Z Yang, X Yang, Y Li, Y Cai, Y Yu, W Zhuang… - European Journal of …, 2023 - Elsevier
The co-administration of anticancer drugs and P-glycoprotein (P-gp) inhibitors was a
treatment strategy to surmount multidrug resistance (MDR) in anticancer chemotherapy. In …
treatment strategy to surmount multidrug resistance (MDR) in anticancer chemotherapy. In …
Discovery of substituted 1, 4-dihydroquinolines as novel promising class of P-glycoprotein inhibitors: First structure–activity relationships and bioanalytical studies
M Hemmer, S Krawczyk, I Simon, A Hilgeroth - Bioorganic & Medicinal …, 2015 - Elsevier
Multidrug resistance (mdr) is the most important problem in the therapeutical treatment of
cancer. One central problem in the resistance proceeding is the expression of …
cancer. One central problem in the resistance proceeding is the expression of …
In Vitro and in Vivo Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Novel Potent Modulator, XR9576
P Mistry, AJ Stewart, W Dangerfield, S Okiji, C Liddle… - Cancer research, 2001 - AACR
The overexpression of P-glycoprotein (P-gp) on the surface of tumor cells causes multidrug
resistance (MDR). This protein acts as an energy-dependent drug efflux pump reducing the …
resistance (MDR). This protein acts as an energy-dependent drug efflux pump reducing the …